Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

Author： Masters Gregory   Brockstein Bruce   Mani Sridhar   Ratain Mark  

Publisher： Humana Press, Inc

ISSN： 1357-0560

Source： Medical Oncology, Vol.20, Iss.1, 2003-03, pp. : 7-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

By Sausville Edward   LoRusso Patricia   Carducci Michael   Carter Judith   Quinn Mary   Malburg Lisa   Azad Nilofer   Cosgrove David   Knight Richard   Barker Peter   Zabludoff Sonya   Agbo Felix   Oakes Patricia   Senderowicz Adrian  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 539-549

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer

By Marshall John   Shapiro Geoffrey I   Uttenreuther-Fischer Martina   Ould-Kaci Mahmoud   Stopfer Peter   Gordon Michael S  

Future Oncology, Vol. 9, Iss. 2, 2013-02 ,pp. : 271-281

Future Medicine

Access to resources Recommend Favorite

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors

By Fury Matthew   Solit David   Su Yungpo   Rosen Neal   Sirotnak F.   Smith Robert   Azzoli Christopher   Gomez Jorge   Miller Vincent   Kris Mark   Pizzo Barbara   Henry Roxanne   Pfister David   Rizvi Naiyer  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 4, 2007-03 ,pp. : 467-475

Springer Publishing Company

Access to resources Recommend Favorite

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

By Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 623-630

Springer Publishing Company

Access to resources Recommend Favorite

Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study

By Frasci Giuseppe   Comella Pasquale   Thomas Renato   Bonito Maurizio   Lapenta Liliana   Capasso Immacolata   Botti Gerardo   Vallone Paolo   Rosa Vincenzo   D'Aiuto Giuseppe   Comella Giuseppe  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 1, 2004-01 ,pp. : 25-32

Springer Publishing Company

Access to resources Recommend Favorite